Terranet AB (TERRNT_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's event with Gubra, and the focus for today's event will of course be the cancelled half-year contract that came earlier this morning, but also the adjustment to Outlook for 2025, which came last night. And from Gubra, as always, the CEO Henrik Blau and CFO Christian Borbos are also participating, and he will come into the picture when he will present. As always, this event will of course be recorded, and when we have edited the event, we will share it on our platform, and I'm sure Goob will also like to do it on theirs. And as usual, I would like to welcome all investors to this event, and as always, if you have any questions, then ask the questions, and I will give them to Henrik and Christian afterwards. So with that said, I would like to welcome you, Henrik, and take care. Thank you, Klaus, and also from my side, welcome to those who are listening today. We have had the pleasure of presenting the results from the first half of this year, and we have, as usual, taken some slides with us. First of all, quite briefly, who is Gubber? Well, we are experts in metabolic diseases. We have a lot of focus on birth and overweight, but also on other diseases related to metabolism. We have a hybrid business model, where the expertise we have built up within the early research of these diseases, we sell as a service, research services to other companies, and that is among other things 16 of the world's 20 largest pharmaceutical companies that are customers in our service business. But we also use this expertise to model our own programs, and that's what we call Discovery and Partnerships, where we model the programs to the right place, and then we engage in partnerships. And today we are about 275 colleagues, and we have a long history with growth, and it is e...